(The 4th CIIE) Blockbuster innovative products frequently appear in foreign pharmaceutical companies to help "Healthy China"

　　China News Service, Shanghai, November 6th (Reporter Jiang Yu) The Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment (RDPAC) launched an initiative at the 4th China International Import Expo on the 6th, in the past five years China's pharmaceutical innovation ecology Based on the achievements of the system development, we call on all walks of life to work together for the next five years of building China's pharmaceutical innovation ecosystem.

The Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment has initiated an initiative to co-create a new future for the pharmaceutical innovation ecosystem.

Photo by Jiang Yu

　　Yuan Gaoqiang, vice president of the China Association of Enterprises with Foreign Investment, said: China has always attached great importance to pharmaceutical innovation and continuously improved the business environment. It is hoped that the majority of multinational pharmaceutical companies will continue to actively participate in the construction of China's high-quality pharmaceutical innovation system, increase investment, and innovate for pharmaceuticals. International cooperation proposes more constructive plans to jointly contribute to the global public health cause and help mankind overcome the new crown epidemic as soon as possible.

　　RDPAC Executive President Conway said: "The successive births of vaccines and therapeutic drugs have shown us the dawn of coping with the challenges of the new crown, restoring life and economic and social development. It is of great significance to encourage innovation in medicine and overcome the challenges of diseases. RDPAC looks forward to working with the Chinese government. Local industry partners continue to work together to allow China's pharmaceutical innovation ecosystem to develop with higher quality."

　　At this year's CIIE, participating foreign companies have shown blockbuster innovative products, and used the platform of the CIIE to expand their "circle of friends" and carry out more in-depth cooperation with Chinese partners.

PerkinElmer's first one-stop platform for vaccine and drug development in Asia.

Photo by Jiang Yu

　　PerkinElmer has not only brought its Asia-first one-stop platform for vaccine and drug research and development, China’s first newborn screening management software, integrated AIDS diagnosis and treatment solutions, and many other new products, but also invited many of its acquisitions this year. "Invisible champion" companies in a subdivision of fields were present to fully display multi-dimensional overall health solutions such as drug research and development, therapy promotion, accurate diagnosis, and drug quality control, and 30 innovative high-tech products made their debut.

　　On the morning of the 6th, four local companies, Qingdao Biomarker Biotechnology Co., Ltd., Shanghai Titan Technology Co., Ltd., Sinopharm (Shanghai) Medical Device Industrial Co., Ltd., and Hefei Ruipu Technology Co., Ltd., signed a strategy with PerkinElmer. The cooperation agreement is jointly committed to promoting the development of cutting-edge detection technology, biotechnology and medical and health undertakings.

Dr. Zhu Bing, Vice President of PerkinElmer and General Manager of Sales and Services in Greater China, said: “I believe that the strong alliance between us will be able to provide more comprehensive and more suitable products for the fields of biomedicine, precision diagnosis and treatment, and scientific research. Products and services for the Chinese market".

　　On the 6th, the cooperation between Novo Nordisk and the China Cardiovascular Health Alliance was officially launched. The two parties will work together to build the "Cardiovascular and Metabolism Academy", and use the alliance platform to carry out multi-channel and multi-form academic exchange activities to convey cardiovascular diseases and metabolic diseases such as diabetes. To further promote the standardization of comprehensive management of cardiovascular and metabolic diseases, we will jointly explore a standardized diagnosis and treatment model that is patient-centered and multidisciplinary cooperation.

The project plans to cover about 4,000 doctors in about 300 hospitals within a year.

　　The prevention and treatment of major chronic diseases such as cardiovascular and cerebrovascular diseases and diabetes is one of the priorities of the "Healthy China Action (2019-2030)".

Academician Ge Junbo, Chairman of the Chinese Cardiovascular Health Alliance, said at the launching ceremony: "I hope that the extensive coverage of the'Cardiovascular and Metabolism Institute' project can promote cardiovascular doctors' understanding and attention to the management of cardiovascular and metabolic diseases, and jointly explore effective comprehensive management methods." .

　　Novo Nordisk also signed a strategic cooperation memorandum with Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (Lecheng Administration) on the same day.

The cooperation between the two parties will focus on the field of chronic diseases, with the introduction of innovative drugs, doctor training, and chronic disease management models as entry points, accelerate the introduction of Novo Nordisk’s latest scientific research results, and promote the first trial of innovative drugs and equipment and academic exchanges, etc. The comprehensive deepening of cooperation in this regard will enable the majority of chronic disease patients in China to benefit from global innovative treatments for the first time without going abroad.

　　Baxter Medical has brought the "China First Show" of Ecodextrin Peritoneal Dialysis Solution (Aitujia) at this CIIE. This is a world-leading innovative drug that is suitable for end-stage renal disease (ESRD). ) The patient's continuous ambulatory peritoneal dialysis (CAPD) single time a day for long-term abdominal retention (8 hours to 16 hours) treatment.

　　Xu Runhong, President of Baxter Healthcare Greater China, said: “On the occasion of the 90th anniversary of Baxter Healthcare’s establishment, I am very pleased to use the CIIE to fully display Baxter’s four major areas of peritoneal dialysis, hemodialysis, acute and severe, and perioperative. Link’s innovative solutions, I believe that the arrival of Atoka’s new peritoneal dialysis fluid will bring more benefits and new treatment options for Chinese peritoneal dialysis patients. Baxter will root China with innovative genes, invest in China, and work together Build a'Healthy China 2030'." (End)